Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials - PubMed (original) (raw)
Clinical Trial
Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials
Richard Shikiar et al. Health Qual Life Outcomes. 2003.
Abstract
Background: Two Phase III randomized controlled clinical trials were conducted to assess the efficacy, safety, and tolerability of weekly subcutaneous administration of efalizumab for the treatment of psoriasis. Patient reported measures of psoriasis-related functionality and health-related quality of life and of psoriasis-related symptom assessments were included as part of the trials.
Objective: To assess the reliability, validity, and responsiveness of the patient reported outcome measures that were used in the trials - the Dermatology Life Quality Index (DLQI), the Psoriasis Symptom Assessment (PSA) Scale, and two itch measures, a Visual Analog Scale (VAS) and the National Psoriasis Foundation (NPF) itch measure.
Methods: Subjects aged 18 to 70 years with moderate to severe psoriasis for at least 6 months were recruited into the two clinical trials (n = 1095). Internal consistency reliability was evaluated for all patient reported outcomes at baseline and at 12 weeks. Construct validity was evaluated by relations among the different patient reported outcomes and between the patient reported outcomes and the clinical assessments (Psoriasis Area and Severity Index; Overall Lesion Severity Scale; Physician's Global Assessment of Change) assessed at baseline and at 12 weeks, as was the change over the course of the 12 week portion of the trial.
Results: Internal consistency reliability ranged from 0.86 to 0.95 for the patient reported outcome measures. The patient reported outcome measures were all shown to have significant construct validity with respect to each other and with respect to the clinical assessments. The four measures also demonstrated significant responsiveness to change in underlying clinical status of the patients over the course of the trial, as measured by the independently assessed clinical outcomes.
Conclusions: The DLQI, the PSA, VAS, and the NPF are considered useful tools for the measurement of dermatology-related limitations of functional ability and the frequency, severity and impact of psoriasis symptoms on patients' lives and psoriasis-related quality of life.
Similar articles
- The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. Shikiar R, et al. Health Qual Life Outcomes. 2006 Sep 27;4:71. doi: 10.1186/1477-7525-4-71. Health Qual Life Outcomes. 2006. PMID: 17005043 Free PMC article. Clinical Trial. - Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A. Krueger GG, et al. Br J Dermatol. 2005 Dec;153(6):1192-9. doi: 10.1111/j.1365-2133.2005.06948.x. Br J Dermatol. 2005. PMID: 16307657 Clinical Trial. - Outcomes in randomized controlled trials in psoriasis: what has changed over the last 20 years?
Morsy H, Kamp S, Jemec GB. Morsy H, et al. J Dermatolog Treat. 2007;18(5):261-7. doi: 10.1080/09546630701487635. J Dermatolog Treat. 2007. PMID: 17917937 Review. - Quality of life in psoriasis patients.
Augustin M, Radtke MA. Augustin M, et al. Expert Rev Pharmacoecon Outcomes Res. 2014 Aug;14(4):559-68. doi: 10.1586/14737167.2014.914437. Epub 2014 May 12. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 24820452 Review.
Cited by
- Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic Review.
Pérez-Chada LM, Hopkins ZH, Balak DMW, Rashid S, Creadore A, Chu B, Villa C, Woodbury MJ, Armstrong AW, Strand V, Gottlieb AB, Merola JF, Barbieri JS. Pérez-Chada LM, et al. JAMA Dermatol. 2024 May 1;160(5):550-563. doi: 10.1001/jamadermatol.2023.5439. JAMA Dermatol. 2024. PMID: 38265774 Review. - Dermatology Life Quality Index in Patients with Psoriasis Treated with Biologic Versus Non-biologic Treatment in Malaysia: A Retrospective Cross-Sectional Study.
Robinson S, Moon TM, Eng TK, Yuen TT, Jong TJ, Selvarajah L, Chiang TW, Chiat TY, Tiong J, Chinthapatla H, Eng SK, Thevarajah S. Robinson S, et al. Drugs Real World Outcomes. 2023 Jun;10(2):291-298. doi: 10.1007/s40801-023-00359-1. Epub 2023 Feb 25. Drugs Real World Outcomes. 2023. PMID: 36840826 Free PMC article. - Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology.
Snyder AM, Chen SC, Chren MM, Ferris LK, Edwards LD, Swerlick RA, Flint ND, Cizik AM, Hess R, Kean J, Secrest AM; Dermatology PRO Consortium. Snyder AM, et al. Am J Clin Dermatol. 2023 Jul;24(4):499-511. doi: 10.1007/s40257-023-00758-8. Epub 2023 Feb 1. Am J Clin Dermatol. 2023. PMID: 36723756 Free PMC article. - New-Onset Guttate Psoriasis: A Long-Term Follow-Up Study.
Galili E, Levy SR, Tzanani I, Segal O, Lyakhovitsky A, Barzilai A, Baum S. Galili E, et al. Dermatology. 2023;239(2):188-194. doi: 10.1159/000527737. Epub 2022 Dec 8. Dermatology. 2023. PMID: 36481593 Free PMC article. - Development and validation of the psoriasis scale among the system of quality of life instruments for chronic diseases QLICD-PS (V2.0).
Liu Q, Feng L, Wan C, Tan J, Yu J, Wang L. Liu Q, et al. Health Qual Life Outcomes. 2022 Apr 22;20(1):68. doi: 10.1186/s12955-022-01970-6. Health Qual Life Outcomes. 2022. PMID: 35459208 Free PMC article.
References
- de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144:33–6. - PubMed
- Finlay AY. Quality of life assessments in dermatology. Seminars Cutan Med Surg. 1998;17:291–6. - PubMed
- Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–4. - PubMed
- Wahl A. The impact of psoriasis on psychosocial life domains. A review. Scand J Caring Sci. 1997;11:243–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous